IT is generally agreed that the muscular weakness and exaggerated proneness to fatigue characteristic of myasthenia gravis are related to a failure of neuromuscular transmission. The mechanism ...
NMD Pharma has raised €38 million ($47 million) to advance two orphan neuromuscular disease programs through clinical proof of concept. The series A equips NMD to learn whether the evidence of ...
Although significant progress has been made over the last 25 years to identify genetic abnormalities associated with congenital myasthenic syndromes (CMS), many patients remain genetically undiagnosed ...
AFTER transection of a motor nerve, the severed part of the axon undergoes progressive changes known as Wallerian degeneration. But before the degenerating axon loses its ability to conduct action ...
New data suggest motor function improves with amifampridine. New phase 2 data for the spinal muscular atrophy (SMA) therapy amifampridine (Ruzurgi) suggests the drug is safe and effective at improving ...
Sitt Wai Fong, Ian S. McLennan, Andrew McIntyre, Jayne Reid, Kathleen I. J. Shennan, Guy S. Bewick, Lynn T. Landmesser Proceedings of the National Academy of Sciences of the United States of America, ...
Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms100% of patients on telitacicept ...
The updated 2025 anesthesia monitoring guidelines from JSA now state that neuromuscular blockade must be quantitatively assessed, and that before extubation, a Train-of-Four (TOF) ratio exceeding 0.9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback